💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Belgium's Omega has high hopes for cell phone chip

Published 12/09/2008, 10:21 AM
Updated 12/09/2008, 10:25 AM
OMEP
-

BRUSSELS, Dec 9 (Reuters ) - Belgian health products distributor Omega Pharma will launch a chip it claims can counter potentially damaging radiation from mobile phones and has high hopes for its sales.

The company, which sells non-prescription products such as wart treatments, pregnancy tests and sun tan lotions to pharmacists, unveiled the E-waves phone chip on Tuesday, a day before its launch in Belgium.

Testing of the chip, which offsets the electromagnetic radiation from the phone, showed it lessened symptoms such as headaches and loss of concentration that might be associated with mobile phone use, Omega said.

It also neutralised the heating effect within the body produced by electromagnetic signals.

Testing of consumers appetite for the product, costing 38.95 euros ($50.1), will start on Wednesday.

The company will only have 30,000 of the chips available on day one, but believes it can ramp up production easily for foreign expansion.

"If we need 10 million, then we'll go for that," Chief Executive Marc Coucke told Reuters on the sidelines of the launch, although he said that was not a forecast.

Coucke and the scientists who have developed the chip argue there is a growing body of evidence showing a link between mobile phone use and the growth of tumours.

"It's like smoking. Eventually we reached a point where the health impact is widely acknowledged," Coucke said.

However, scientists worldwide remain split between those that believe there is a risk and others who believe there is insufficient evidence to show mobile phones are unsafe.

Omega, which has exclusive international distribution rights, will begin selling the product in other countries from early 2009. It will also launch three similar devices designed for use in the car, linked to a computer and in the home.

Omega competes with the over-the-counter arms of pharma giants such as Johnson & Johnson and Bayer and of consumer products groups such as Procter & Gamble.

Omega, the only sizeable stand-alone OTC company, ranks itself 11th in the world in that market. It is mainly active in western Europe, but is also pushing into eastern Europe. (Reporting by Philip Blenkinsop; Editing by Jon Loades-Carter)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.